In the family of anti-obesity treatments, here is Wegovy, cousin of the famous anti-diabetic Ozempic, very popular across the Atlantic by influencers for its weight-loss properties. Considered a miracle product, this new drug, developed by the Danish laboratory Novo Nordisk, has now been authorized in France for a week.
For now, there is no need to salivate thinking about being able to eliminate a few extra pounds in record time, nor to rush to pharmacies in the hope of obtaining a box, this treatment which comes in the form of “pre-filled injector pens allowing patients to inject a dose each week with gradual dosing“, will not be accessible to anyone who wants it. The National Medicines Safety Agency (Ansm) has set a framework. “Wegovy is reserved for people under 65 years of age and suffering from severe obesity, that is to say those with a body mass index greater than 35 kg/m².“In addition, initial prescriptions will be carried out by a doctor specializing in endocrinology-diabetology-nutrition. On the other hand, prescription renewals may be carried out by general practitioners. These restrictions put in place by the ANSM, mark a desire to fight against the misuse of these drugs for aesthetic purposes by “people without weight-related health problems“.
